New PBS listing for people with severe dry eyes and deteriorating diabetic control
Patients with deteriorating diabetic control and people who have severe dry eyes will benefit from changes to the Pharmaceutical Benefits Scheme (PBS) introduced from 1 February 2008.
The extension to the listing of piolitazone hydrochloride (Actos®) means a further medication option for patients with deteriorating type 2 diabetic control. Actos helps the body to use insulin.
This extended listing will allow doctors to prescribe piolitazone hydrochloride in triple oral combination therapy with the anti-diabetic drugs metformin and sulfonylurea. It is expected to benefit about 6,000 patients between 2008 and 2012, at no additional cost to the PBS and Repatriation Pharmaceutical Benefits Scheme.
The listing of tamarindus indica seed polysaccharide (Visine Professional®) has been extended to allow it to be prescribed by optometrists. Visine Professional is a lubricant eye drop that helps people who have severe dry eyes. The single-use eye drop will provide another option for optometrists to treat patients with severe dry eyes who are sensitive to preservatives. This listing is expected to be cost neutral and will serve existing patient populations.
